IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

Rhea-AI Summary

IN8bio (Nasdaq: INAB) announced upcoming presentations of new clinical and preclinical data from its gamma-delta T cell therapies platform at major scientific conferences. The company will showcase its research at four prestigious events: AACR 2025, ISCT 2025, ASGCT 2025, and ASCO 2025.

Key presentations include:

• A novel gamma-delta T cell engager platform for cancer immunotherapy at AACR
• Manufacturing processes and TCR repertoire analysis at ISCT
• INB-600 T cell engager platform and molecular signatures at ASGCT
• Phase 1 study results of INB-200 in glioblastoma patients at ASCO

CEO William Ho emphasized the scientific rigor and clinical potential of their platform, highlighting applications in both oncology and immune-mediated diseases. The presentations will focus on their INB-200/400 program in glioblastoma and novel T cell engager technologies.

Positive

• Multiple clinical data presentations across major scientific conferences (AACR, ISCT, ASGCT, ASCO) demonstrating broad scientific validation
• Phase 1 study results of INB-200 in glioblastoma to be presented at ASCO, indicating clinical progress
• Expanding therapeutic applications beyond oncology into autoimmune diseases, showing pipeline diversification
• Robust manufacturing capabilities and quality management systems in place for cell therapy production

Negative

• Early-stage clinical pipeline with no approved products yet
• No specific efficacy or safety data disclosed in the press release
• Operating in highly competitive cell therapy space requiring significant R&D investment

Insights

Biotechnology/Pharmaceutical Analyst

IN8bio's upcoming presentation of Phase 1 glioblastoma data at ASCO shows clinical pipeline progress in an area of high unmet need.

IN8bio's announcement of multiple scientific presentations demonstrates meaningful progress in their gamma-delta T cell therapy platform development. The oral presentation at ASCO for their Phase 1 INB-200 study in newly diagnosed glioblastoma multiforme (GBM) is particularly significant, as oral slots undergo competitive selection by conference reviewers.

The company will present data across four major scientific conferences (AACR, ISCT, ASGCT, and ASCO), covering both clinical applications and technical aspects of their platform. This multi-conference approach highlights IN8bio's comprehensive development strategy spanning oncology and potentially autoimmune diseases.

The GBM program deserves special attention as this brain cancer has seen minimal therapeutic innovation despite dismal outcomes. Standard treatment includes surgery, radiation, and temozolomide chemotherapy, with IN8bio evaluating their gamma-delta T cell therapy alongside maintenance temozolomide.

While these presentations represent important scientific communication milestones, investors should understand that Phase 1 studies primarily establish safety with preliminary efficacy signals. No actual clinical data is previewed in this announcement, preventing assessment of therapeutic impact.

For clinical-stage biotechnology companies, securing presentation slots at prestigious conferences like ASCO validates their approach within the scientific community and represents important developmental progress in their clinical pathway.

Oncology Expert

Phase 1 gamma-delta T cell therapy data for newly diagnosed glioblastoma addresses critical need for innovation in this devastating brain cancer.

The upcoming ASCO presentation of IN8bio's INB-200 Phase 1 study targets one of oncology's most challenging malignancies. Glioblastoma multiforme (GBM) carries a dismal prognosis with median survival of approximately 15 months despite aggressive standard treatment, and the field has seen minimal therapeutic advances for decades.

What makes IN8bio's approach scientifically interesting is their use of gamma-delta T cells, which differ fundamentally from conventional alpha-beta T cell therapies. These cells recognize stress signals common in cancer without requiring MHC-restricted antigen presentation, potentially overcoming key solid tumor resistance mechanisms.

The gene modification mentioned likely enhances tumor-targeting or persistence. By focusing on newly diagnosed rather than recurrent GBM, the therapy intervenes when tumor burden may be lower and before treatment resistance fully develops - a sensible clinical strategy.

The integration with standard temozolomide maintenance therapy represents a pragmatic approach that builds upon established treatment paradigms rather than replacing them, potentially facilitating clinical adoption if successful.

Phase 1 studies primarily establish safety and feasibility, with efficacy as secondary objectives. The selection for oral presentation format suggests the abstract contained information deemed scientifically noteworthy by peer reviewers, though without the actual data, clinical impact remains to be determined at the conference.

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that it will present new clinical and preclinical data from its pipeline of gamma-delta T cell therapies at several upcoming scientific conferences.

“The breadth of data we’re presenting at upcoming medical conferences reflects the scientific rigor and clinical potential of IN8bio’s gamma-delta T cell platform,” said William Ho, CEO and co-founder, IN8bio. “From our INB-200/400 program in newly glioblastoma to our novel T cell engager technologies, we are expanding the therapeutic applications of this unique class of therapies. These presentations highlight IN8bio’s capabilities, know-how in manufacturing, and the clinical potential of our programs to help patients with significant unmet needs across oncology and immune-mediated diseases.”

Upcoming presentations:

American Association for Cancer Research (AACR) 2025

Poster Title: A novel gamma-delta T cell engager platform for cancer immunotherapy
Abstract Presentation Number: 7321 (Poster Board 7)
Session Title: Immunology/T Cell Engagers and Novel Antibody-Based Therapies
Date/Time: Wednesday, April 30, 2025, 9:00 – 12:00 PM CDT
Location: McCormick Place Convention Center, Chicago, IL
More information: www.aacr.org/meeting/aacr-annual-meeting-2025/abstracts.

International Society for Cell & Gene Therapy (ISCT) 2025

Oral Presentation Title: From Donor to Therapy: How Robust Manufacturing Shapes the TCR Repertoire and Cytotoxic Power of Donor-Derived Allogeneic ex vivo Expanded and Activated γδ T Cell Products*
Date/Time: Friday, May 9, 2025, 3:00 – 4:00 PM CDT
Presenter: Mariska ter Haak, Senior Director Analytical Development, IN8bio
Session: Oral Abstract Session – Immunotherapy (CAR-T, T Reg, NK Cells etc.)
*Host Region (US East) Abstract Award

Poster Presentation Title: Selection and Implementation of the Electronic Quality Management System for High Complexity Clinical Stage Cellular Therapy Company
Date/Time: Thursday, May 8, 2025, 6:00 - 7:30 PM CDT
Presenter: Guoling Chen, Senior Director of Quality Operations, IN8bio
More information: https://isctglobal.org

American Society of Gene & Cell Therapy (ASGCT) 2025 Conference

Poster Presentation Title: INB-600: A Novel T Cell Engager Platform Specific for gamma-delta (γδ) T cells
Date/Time: Thursday, May 15, 2025, Time: 5:30 - 7:00 PM CDT
Presenter: Lawrence Lamb, Ph.D., Co-Founder and Chief Scientific Officer, IN8bio
Location: Poster Hall I2, New Orleans Ernest N. Morial Convention Center

Oral Presentation Title: Decoding the Molecular Signature of Expanded Gamma-delta T Cell Products; TCR and Immune Gene Expression from Allogeneic derived Products
Title: Molecular and Cellular Methods - Applications
Date/Time: Saturday, May 17, 2025, 10:30 - 10:45 AM CDT
Presenter: Mariska ter Haak, Senior Director Analytical Development, IN8bio
Location: NOLA Theater B, New Orleans Ernest N. Morial Convention Center
More information: https://annualmeeting.asgct.org

American Society of Clinical Oncology (ASCO) 2025

Oral Presentation Title: INB-200: Phase 1 study of gene-modified autologous gamma-delta (γδ) T cells in newly diagnosed glioblastoma multiforme (GBM) patients receiving maintenance temozolomide (TMZ).
Presenter: Louis “Burt” Nabors, MD
Abstract #: 2007
Session: Central Nervous System Tumors
Session Type: Oral Abstract Session
Session Date and Time: May 30, 2025, 2:45 - 5:45 PM CDT
Presentation Time/Duration: 4:57 - 5:09 PM CDT
More information: https://meetings.asco.org/abstracts-presentations/252921

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell-based immunotherapies for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic γδ T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI γδ T cells, in combination with standard of care, for glioblastoma, and advancing novel γδ T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.

Forward-Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the ability of the INB-600 platform to offer a scalable, flexible, more precise and more powerful alternative to conventional CD3-based approaches and have applications in autoimmune diseases as well as cancer; IN8bio’s plans to expand its pipeline beyond genetically engineered and drug-resistant cellular therapy and explore various disease indications and any opportunities for partnership with the INB-600 platform; and other statements that are not historical fact. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may be unable to raise additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of its development programs, or even terminate its operations; IN8bio’s ability to continue to operate as a going concern; the risk that IN8bio may not realize the intended benefits of its γδ-TCE platform or DeltEx platform; the availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; the uncertainty of regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section entitled “Risk Factors” in IN8bio’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 13, 2025, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Contacts:

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

FAQ

What clinical data will IN8bio (INAB) present at ASCO 2025?

IN8bio will present Phase 1 study results of INB-200, their gene-modified autologous gamma-delta T cell therapy for newly diagnosed glioblastoma patients receiving maintenance temozolomide. The presentation is scheduled for May 30, 2025, from 4:57-5:09 PM CDT.

Which gamma-delta T cell programs is IN8bio (INAB) developing in 2025?

IN8bio is developing multiple gamma-delta T cell programs, including INB-200/400 for glioblastoma, a novel T cell engager platform, and donor-derived allogeneic therapies. These programs target both cancer and autoimmune diseases.

What is IN8bio's (INAB) presentation schedule at AACR 2025?

At AACR 2025, IN8bio will present a poster (Abstract #7321) on their novel gamma-delta T cell engager platform for cancer immunotherapy on Wednesday, April 30, 2025, from 9:00 AM to 12:00 PM CDT at McCormick Place Convention Center, Chicago.

How is IN8bio (INAB) advancing their manufacturing capabilities for gamma-delta T cell therapies?

IN8bio will present their manufacturing advances at ISCT 2025, focusing on donor-derived allogeneic ex vivo expanded gamma-delta T cell products and their electronic quality management system implementation for cellular therapy production.

What are the key presentations for IN8bio (INAB) at ASGCT 2025?

At ASGCT 2025, IN8bio will present two key studies: a poster on INB-600 (their novel T cell engager platform) on May 15, and an oral presentation on molecular signatures of expanded gamma-delta T cell products on May 17 in New Orleans.